vimarsana.com

Latest Breaking News On - Biopharmaceuticals business unit - Page 9 : vimarsana.com

AstraZeneca s Farxiga approved by the FDA for heart failure

AstraZeneca's Farxiga approved by the FDA for heart failure

United kingdomGreat britainAstrazeneca farxigaDrug administrationEuropean unionExecutive vice presidentBiopharmaceuticals business unitNew england journalNature medicine

FDA Expands Dapagliflozin Label to Include Reducing Risk of CV Death in Heart Failure

Announced just more than a year after AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular death and HF hospitalizations for dapagliflozin based on results of the phase 3 DELIVER trial.

United statesCampbellp dapagliflozinStephen greeneDrug administrationEuropean society of cardiologyDuke university school of medicineHeart failure society of americaEuropean societyRuud dobberBiopharmaceuticals business unitHeart failure societyGet with the guidelines heart failureDuke university school

AstraZeneca (AZN) Farxiga Extended in the US to Reduce Risk of Cardiovascular Death and Hospitalisation for Heart Failure to a Broader Range of Patients

AstraZeneca (AZN) Farxiga Extended in the US to Reduce Risk of Cardiovascular Death and Hospitalisation for Heart Failure to a Broader Range of Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomGreat britainEuropean unionDrug administrationExecutive vice presidentBiopharmaceuticals business unitNew england journalNature medicine

FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients

FDA approval means patients with heart failure can benefit from FARXIGA regardless of left ventricular ejection fraction status . | May 9, 2023

United statesUnited kingdomGreat britainGeriatr cardiolColl cardiolA report from the american heart associationAmerican heart associationDrug administrationEuropean unionCompany on twitter astrazenecaExecutive vice presidentBiopharmaceuticals business unitNew england journalNature medicineDiabetes mellitusMycotic infections

FDA Approves Expanded Label for Dapagliflozin to Reduce Risk of Cardiovascular Death, Hospitalization from Heart Failure

Dapagliflozin was established as the first SGLT2 inhibitor that demonstrated a mortality benefit for cardiovascular death from heart failure.

United statesUnited kingdomGreat britainEuropean unionNew england journalBiopharmaceuticals business unit

vimarsana © 2020. All Rights Reserved.